Fluoroalkyl Camptothecin ADCs for Controlled Tumor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The number of marketed antibody-drug conjugates (ADCs) using camptothecin derivatives as payloads is limited, necessitating the exploration of new structures for camptothecin derivatives and suitable linkers to enhance anti-tumor activity.
Innovation Solution
Development of antibody-drug conjugates utilizing fluoroalkyl substituted camptothecin derivatives, specifically represented by Formula (I), with defined drug-to-antibody ratios (DAR) ranging from 2-8, including structures like Formula (I-1) to (I-6), using specific linkers and antibodies such as HS627 and IP140B, to target tumor-associated antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional camptothecin derivatives are used as ADC payloads, then the structure is well-established, but the number of marketed ADC drugs is limited and anti-tumor activity needs enhancement
Solution Approach 1:
The patent applies parameter changes by systematically modifying the camptothecin derivative structure through fluoroalkyl substitution at different positions (R1, R2, R3, R4 groups) and varying linker configurations to optimize anti-tumor activity while maintaining structural feasibility for ADC development
Solution Approach 2:
The patent creates composite structures by combining camptothecin derivatives with various linker types (L1, L2, L3, Lz linkers) and antibody components to form ADC conjugates with enhanced therapeutic properties and targeted delivery capabilities
2Quantity of substance
If the drug-to-antibody ratio (DAR) is increased to enhance therapeutic effect, then anti-tumor activity improves, but the stability and manufacturability of the ADC may be compromised
Solution Approach 1:
The patent optimizes the drug-to-antibody ratio by selecting specific fluoroalkyl substituted camptothecin derivatives with appropriate molecular weights and conjugation properties, achieving a balance between therapeutic efficacy and ADC stability through precise structural parameter control
3Productivity
If new camptothecin derivative structures are explored to increase anti-tumor activity, then therapeutic efficacy improves, but the manufacturing complexity and development time increase
Solution Approach 1:
The patent segments the ADC development into modular components: standardized fluoroalkyl substituted camptothecin derivative cores, interchangeable linker types (L1-Lz), and antibody conjugation modules, enabling systematic optimization while simplifying manufacturing through modular assembly
Solution Approach 2:
The patent develops universal fluoroalkyl substituted camptothecin derivative structures that can be conjugated through multiple linker types and applied to various antibody targets, creating a platform technology that reduces development time and manufacturing complexity across different ADC candidates
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An oxycycloalkyl-substituted camptothecin derivative used as an antibody-drug conjugate represented by formula (I) in the drug toxicity portion. The antibody-drug conjugate has a significant antitumor effect.